CA2890105C — Treatment of cancers using pi3 kinase isoform modulators
Assigned to Infinity Pharmaceuticals Inc · Expires 2023-03-21 · 3y expired
What this patent protects
Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor having the following structure: (see above formula) for treating cancers or hematologic disorders, which compound is also referred to herein as Compound 292.
USPTO Abstract
Provided herein are methods, kits, and pharmaceutical compositions that include a PI3 kinase inhibitor having the following structure: (see above formula) for treating cancers or hematologic disorders, which compound is also referred to herein as Compound 292.
Drugs covered by this patent
- Copiktra (DUVELISIB) · Secura
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.